SAN DIEGO, May 11, 2017 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, announced today that it has relocated its product development laboratories and corporate headquarters to a new larger location in San Diego, California. The unification of the headquarters and laboratories will provide increased communication and collaboration between development and the other departments resulting in more efficient development of products.
"We are excited to have found this new location as it will enable Beloteca to continue to grow and internalize development over the next several years," said Fred Defesche, Chief Executive Officer of Beloteca, Inc. "The new space is ideal because it allows us to acquire additional space after obtaining approval of our first products without being encumbered by excess expenses while we are in our startup phase."
The new facility currently spans more than 3,500 square feet and will expand to over 6,000 square feet. The larger space allows Beloteca's to increase its in-house product development capabilities and hire more employees in formulation and analytical development.
Beloteca is a privately held specialty pharmaceutical company. Beloteca's primary focus is to develop, obtain regulatory approval and out license sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. Beloteca currently has an active development pipeline with more than 15 pharmaceutical products in various stages of development. For additional information about the Company, visit the Company's web site at www.beloteca.com.
For further information, please contact Fred Defesche at 512-669-8765 or via email [email protected].
"We are excited to have found this new location as it will enable Beloteca to continue to grow and internalize development over the next several years," said Fred Defesche, Chief Executive Officer of Beloteca, Inc. "The new space is ideal because it allows us to acquire additional space after obtaining approval of our first products without being encumbered by excess expenses while we are in our startup phase."
The new facility currently spans more than 3,500 square feet and will expand to over 6,000 square feet. The larger space allows Beloteca's to increase its in-house product development capabilities and hire more employees in formulation and analytical development.
Beloteca is a privately held specialty pharmaceutical company. Beloteca's primary focus is to develop, obtain regulatory approval and out license sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. Beloteca currently has an active development pipeline with more than 15 pharmaceutical products in various stages of development. For additional information about the Company, visit the Company's web site at www.beloteca.com.
For further information, please contact Fred Defesche at 512-669-8765 or via email [email protected].
RSS Feed